ALBUQUERQUE, N.M. (AP) — It could be well into next year before a COVID-19 vaccine is widely available, but top health officials in New Mexico said Tuesday that they have submitted their plan to the federal government for building the infrastructure, tracking systems and partnerships that will be needed for distribution.
The focus will be on vaccinating health care workers and first responders, then nursing home residents and staff. They acknowledged that supplies will likely be limited early on and immunizations for the general public would come later.… Read More
MEXICO CITY (Reuters) – Mexico will not necessarily follow the U.S. Food and Drug Administration (FDA) in approving Gilead Science Inc’s antiviral drug remdesivir for use in COVID-19 patients, a top Mexican health official said on Friday.
Mexico’s health regulator Cofepris has already twice denied approval for the drug with a “non-favorable” opinion, deputy health minister Hugo Lopez-Gatell told his regular nightly news conference.
“We have no mandate from the FDA,” he said. “Cofepris has identified that the evidence does not suggest a usefulness, a sufficient efficacy.”
The FDA approved remdesivir on Thursday, making it the first and only drug approved for the disease in the United States.
Remdesivir, given intravenously, was one of the drugs used to treat U.S. President Donald Trump during his bout with COVID-19.
The World Health Organization’s (WHO) Solidarity drug trial last week concluded remdesivir has little or no impact on a patient’s chances of surviving COVID-19, and a top WHO scientist on Friday recommended the FDA consider all available evidence.
Lopez-Gatell said Gilead had sent a letter to doctors in Mexico refuting the results of the Solidarity trial, and that officials were looking to see if the letter could be cause for sanction, given that remdesivir is not registered with Mexican health authorities.
“It confuses the population and generates a false expectation of the possibility of having a treatment option,” he said.
Gilead did not immediately respond to a request for comment.
(Reporting by Sharay Angulo and Daina Beth Solomon; Editing by Sonya Hepinstall and Tom Hogue)
ALBUQUERQUE, N.M. (AP) — New Mexico Gov. Michelle Lujan Grisham on Tuesday unveiled more requirements for businesses after a string of record-breaking daily case counts prompted renewed restrictions just last week.
Starting Friday, restaurants, breweries, retail stores, gyms and other businesses will be required to close for two weeks if they have more than four separate incidents of COVID-19 among employees within a 14-day period. Those businesses that have had at least two outbreaks will be listed on the state’s new watch list.… Read More
ALBUQUERQUE, N.M. (AP) — New Mexico Gov. Michelle Lujan Grisham is scheduled Tuesday to provide an update on COVID-19 cases after a string of record-breaking daily case counts prompted more restrictions last week and officials continue to crack down on employers who they say aren’t following the rules.
The state’s Occupational Health and Safety Bureau has opened an investigation of Sandia National Laboratories after receiving a complaint about alleged violations of the state public health order.… Read More
ALBUQUERQUE, N.M. — New Mexico health officials on Friday confirmed the state set another single-day record with 819 COVID-19 cases, bringing the statewide total to 35,770 since the pandemic began.
New rules to limit gatherings to five people or less, reduce hotel capacities and impose a 10 p.m. closing time for bars and some restaurants also took effect Friday after successive days of record-breaking daily infection rates.
The previous record of 672 on Thursday already had eclipsed records set in recent days.
The state on Friday also reported six additional deaths related to the pandemic, bringing that total to 928.
At the University of New Mexico, eight football players and one assistant coach have tested positive for the coronavirus and high positivity rates in the county where the school is located have forced the postponement of practice.
University athletic director Eddie Nuñez said if the team is unable to practice for the next week, they will not be able to safely play their first scheduled game on Oct. 24 against Colorado State.
HERE’S WHAT YOU NEED TO KNOW ABOUT THE VIRUS OUTBREAK:
— France records 30,000 virus cases, highest single-day rise
— WHO study finds remdesivir didn’t help COVID-19 patients
— U.S. testing 3 drugs to try to tamp down coronavirus
— Coronavirus cases are rising in key U.S. presidential battleground states ahead of Election Day.
— White House puts political operatives at CDC to try to control virus information
— Thousands arrive in Hawaii on first day pre-travel testing allowing no quarantine
— Follow AP’s pandemic coverage at http://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak
HERE’S WHAT ELSE IS HAPPENING:
SALT LAKE CITY — One of Utah’s largest hospitals had no beds left Friday in its regular intensive-care unit as the governor declared the state’s weekslong spike in coronavirus cases “unsustainable.”
The University of Utah Health had to set up extra ICU beds staffed by doctors and nurses working overtime to care for its critical patients this week as the unit hit 104% capacity, said Chief Medical Officer Dr. Russell Vinik.
“We’ve cut back where we can but it’s precarious,” he said. “We are very concerned about flu season, particularly if people don’t get vaccinated. We can’t take another hit.”
MIAMI – Florida has reported a slight uptick in daily confirmed COVID-19 cases, adding 3,449 to its total caseload on Friday.
The new state report raises the seven-day average of new infections close to 2,800, a figure that had dropped under 2,300 in late September and early October, when the state lifted restrictions on restaurants and the largest school districts began welcoming students.
The COVID-19 hospitalization and deaths figures have been relatively stable in recent weeks.
The number of people being treated in Florida hospitals peaked in late July at more than 9,500, then declined for about two months. But the figure has leveled off for the past three weeks at around 2,000 to 2,200 without further decline.
The state tallied 98 new virus-related deaths on Friday,
LAS VEGAS, Oct. 15, 2020 (GLOBE NEWSWIRE) — Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announces that it will initiate clinical trials in Mexico to test a medical hypothesis that has been advanced over the last five years that ALS may be caused by vascular disruption in the areas of the brain which house motor neurons, those neurons which become dysfunctional in patients suffering from ALS. The hypothesis is simply that the micro-vascularization in that area of the brain is blocked or narrowed, restricting the flow of blood needed to nourish the motor neurons. Just as with heart disease, where blockage of coronary arteries can lead to angina and heart attacks, that same process is now thought to underlie the development of ALS.
Dr. Jack Jacobs, Zhittya’s President and Chief Science Officer will be giving a free Zoom webinar on this topic entitled: “Amyotrophic Lateral Sclerosis (ALS): Is Therapeutic Angiogenesis a Potential Treatment to Reverse this Disease?” This webinar will broadcast on Thursday, October 29, 2020 at 9:00 am Pacific time, 12 noon Eastern time.
Click Here to Register for this Webinar
Zhittya is developing a biological drug which in previous US FDA-authorized clinical trials has demonstrated it can trigger “therapeutic angiogenesis” or the growth of new blood vessels in ischemic tissues. Zhittya has prepared a White Paper entitled: “Human FGF-1 as a Potential Treatment for Amyotrophic Lateral Sclerosis (ALS)”, which is available to all, free of charge, by emailing: email@example.com
Daniel C. Montano, CEO of Zhittya stated, “I believe we are truly on to something here. Over the last three years, we have continually uncovered data which enhances our belief that therapeutic angiogenesis might be a viable breakthrough treatment for patients that suffer from ALS. If, as we believe, ALS is initiated by micro-vascular disruption in the brain, we hope our molecule can do in the brain, what it has already demonstrated it can do in the US FDA-cleared heart trial, namely, grow new blood vessels.”
Dr. Jack Jacobs added, “ALS is a progressive and fatal neuromuscular disease and the majority of ALS patients die within 2–5 years of receiving a diagnosis. There is no known definitive cause of ALS and hereditary forms of the disease only account for 5%–10% of cases. No cure has been identified and the lack of proven and effective therapies for ALS is an ongoing challenge. There are now multiple lines of evidence that have established that angiogenesis is deficient in this disease, leading directly to the death of motor neurons. I believe therapeutic angiogenesis may be a potentially novel way to halt the progression of ALS and we are pleased that the Mexican regulatory authorities have given us permission to test our biological drug candidate in subjects with ALS.
About Zhittya Genesis Medicine
Zhittya’s management has been working to advance these medicines for over 21 years and many tens of millions of dollars have been expended in preclinical and clinical studies. Zhittya’s medicine initiates a biological process in the human body referred